Daewoong Pharmaceutical Co.

-Daewoong Pharmaceutical publica el mecanismo molecular de la bersiporocina como antifibrótico en EMBO Molecular Medicine Elucidado el mecanismo molecular que subyace a la seguridad y eficacia de Bersiporocina La bersiporocina se encuentra actualmente en fase II de ensayo clínico para la fibrosis pulmonar idiopática SEÚL, Corea del Sur, 26 de mayo de 2023 /PRNewswire/ — Daewoong … Read more

Elucidated molecular mechanism behind safety and efficacy of Bersiporocin Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for … Read more

Elucidated molecular mechanism behind safety and efficacy of Bersiporocin Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for … Read more